A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies

Summary

The primary objective of Phase I of this study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of CTS3497 in patients with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deficient solid tumors and lymphomas. The primary objective of Phase II of this study is to evaluate the efficacy of CTS3497 in patients with metastatic or locally advanced MTAP-deficient solid tumors and lymphomas.

Timeline

Start

2024-12-25

Primary completion

2028-12-31

Completion

2029-06-30

Drugs

Indications